Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 2
2014 2
2015 2
2016 2
2017 2
2018 2
2019 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: van der steen dm. J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14. J Clin Invest. 2019. PMID: 30640174 Free PMC article.
Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, Heemskerk MHM. Bijen HM, et al. Among authors: van der steen dm. Mol Ther. 2018 May 2;26(5):1206-1214. doi: 10.1016/j.ymthe.2018.02.017. Epub 2018 Feb 23. Mol Ther. 2018. PMID: 29567312 Free PMC article.
Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.
de Waard AA, Verkerk T, Hoefakker K, van der Steen DM, Jongsma MLM, Melamed Kadosh D, Bliss S, de Ru AH, Admon A, van Veelen PA, Griffioen M, Heemskerk MHM, Spaapen RM. de Waard AA, et al. Among authors: van der steen dm. iScience. 2021 Jan 9;24(2):102051. doi: 10.1016/j.isci.2021.102051. eCollection 2021 Feb 19. iScience. 2021. PMID: 33554062 Free PMC article.
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ. Gezgin G, et al. Among authors: van der steen dm. JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729. JAMA Ophthalmol. 2017. PMID: 28448663 Free PMC article.
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH. Jahn L, et al. Among authors: van der steen dm. Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4. Blood. 2017. PMID: 28053195 Free article.
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, Morton LT, van der Steen DM, Kweekel C, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: van der steen dm. Mol Ther. 2021 Aug 8:S1525-0016(21)00404-4. doi: 10.1016/j.ymthe.2021.08.010. Online ahead of print. Mol Ther. 2021. PMID: 34371177
HLA monomers as a tool to monitor indirect allorecognition.
Breman E, van Miert PP, van der Steen DM, Heemskerk MH, Doxiadis II, Roelen D, Claas FH, van Kooten C. Breman E, et al. Among authors: van der steen dm. Transplantation. 2014 Jun 15;97(11):1119-27. doi: 10.1097/TP.0000000000000113. Transplantation. 2014. PMID: 24798312 Free PMC article.
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.
Luk SJ, van der Steen DM, Hagedoorn RS, Jordanova ES, Schilham MW, Bovée JV, Cleven AH, Falkenburg JF, Szuhai K, Heemskerk MH. Luk SJ, et al. Among authors: van der steen dm. Oncoimmunology. 2018 Sep 11;7(12):e1507600. doi: 10.1080/2162402X.2018.1507600. eCollection 2018. Oncoimmunology. 2018. PMID: 30524904 Free PMC article.
17 results